Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
There is a direct association between cancer and thrombosis (blood clots). The purpose of
this study is to determine the best dose of an antithrombotic (prevents blood clots) agent
called fondaparinux in non-small cell lung cancer(NSCLC). Patients will also receive
chemotherapy.